Consensus QuidelOrtho Corporation

Equities

QDEL

US2197981051

Real-time Estimate Cboe BZX Other stock markets 02:40:58 2024-05-15 pm EDT			5-day change	1st Jan Change
45.51 ^USD	+3.01%		+6.84%	-38.13%

May. 14	Activist Jana Partners built position in QuidelOrtho in first quarter, sources say	RE
May. 14	Sector Update: Health Care Stocks Rise in Late Afternoon Trading	MT

Evolution of the average Target Price on QuidelOrtho Corporation

Price target over the last 5 years

History of analyst recommendation changes

72d66cc39ee10a3d5.sEO-Zgi4BdAauagDDpZ4t-TzACX-sG5a2Xn8AEZCJHM.wSHkVGTxYpNyytBXfdcTzq2LZ26o9yQqrFSIYRQtUSzYLNQnUY9c4Snh-Q~a9da85008dffcaadaf03b2f2fe8178f6

Analyst Recommendations on QuidelOrtho Corporation

Activist Jana Partners built position in QuidelOrtho in first quarter, sources say	May. 14	RE
Jana Partners Acquires Stake in QuidelOrtho	May. 14	MT
Activist Jana Partners built position in QuidelOrtho in first quarter, sources say	May. 14	RE
RBC Cuts Price Target on QuidelOrtho to $68 From $81, Keeps Outperform Rating	May. 09	MT
UBS Downgrades QuidelOrtho to Sell From Neutral, Adjusts Price Target to $42 From $70	Mar. 04	MT
William Blair Downgrades QuidelOrtho to Market Perform From Outperform	Feb. 14	MT
Citigroup Adjusts Price Target on QuidelOrtho to $50 From $72, Maintains Neutral Rating	Feb. 14	MT
Craig-Hallum Downgrades QuidelOrtho to Hold From Buy, Adjusts Price Target to $50 From $158	Feb. 14	MT
Raymond James Downgrades QuidelOrtho to Outperform From Strong Buy, Cuts Price Target to $76 From $100	Feb. 14	MT
JPMorgan Downgrades QuidelOrtho to Underweight From Neutral, Adjusts Price Target to $37 From $66	Feb. 14	MT
RBC Adjusts PT on QuidelOrtho to $81 From $130, Notes Worse-Than-Anticipated COVID Headwinds; Outperform Kept on 'Compelling' Risk/Reward	Feb. 14	MT
RBC Cuts Price Target on QuidelOrtho to $130 From $140, Keeps Outperform Rating	Dec. 21	MT
Citigroup Downgrades QuidelOrtho to Neutral From Buy, Cuts Price Target to $72 From $95	Dec. 11	MT
Raymond James Adjusts QuidelOrtho's Price Target to $110 From $130, Keeps Strong Buy Rating	23-08-15	MT
RBC Raises QuidelOrtho's Price Target to $136 From $133, Keeps Outperform Rating	23-07-17	MT
UBS Adjusts QuidelOrtho Price Target to $98 From $99, Maintains Neutral Rating	23-05-17	MT
RBC Boosts Price Target on QuidelOrtho to $133 From $130, Maintains Outperform Rating	23-05-04	MT
RBC Cuts Price Target on QuidelOrtho to $130 From $136, Maintains Outperform Rating	23-04-14	MT
RBC Cuts Price Target on QuidelOrtho to $130 From $136, Maintains Outperform Rating	23-04-13	MT
UBS Adjusts QuidelOrtho Price Target to $99 From $93, Maintains Neutral Rating	23-02-22	MT
Raymond James Cuts QuidelOrtho's Price Target to $130 From $136, Maintains Strong Buy Rating	23-02-16	MT
RBC Raises Price Target on QuidelOrtho to $136 From $125 After 'Strong' Q4, Above-Street 2023 Guidance, Maintains Outperform Rating	23-02-16	MT
Citigroup Upgrades QuidelOrtho to Buy From Neutral, Adjusts Price Target to $125 From $90	22-12-12	MT
RBC Initiates QuidelOrtho at Outperform With $125 Price Target, Sees Potential for Market Share Gains, Sales Acceleration Beyond 2024	22-12-07	MT
UBS Adjusts QuidelOrtho Price Target to $93 From $86, Maintains Neutral Rating	22-11-04	MT